Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 6:54 AM

Ark Therapeutics plc

Type: Company
Name: Ark Therapeutics plc (Ark Therapeutics Group plc)
First Reported 10/29/2009 - Updated 10/29/2009 - 2 Documents
Circadian Technologies subsidiary terminates licence to Ark Therapeutics
Circadian Technologies Limited (ASX:CIR), a developer of novel, biologics-based treatments for cancer, announced today that its subsidiary Vegenics Limited has terminated the licence previously granted to Ark Therapeutics Limited, under its VEGF-D gene ... [Proactiveinvestors United Kingdom RSS feed - 10/29/2009]
First Reported 11/03/2009 - Updated 11/03/2009 - 1 Documents (in Space Science)
easyJet plc - Click to view image in its original context
easyJet plc
Core-satellite approach comes into its own
As stock markets recover a mix of long and short-term bets will really start to deliver, says Caspar Trenchard of Standard Life Investments.We employ a core and satellite approach to portfolio construction. The past year has been the best and worst for ... [Citywire - 11/03/2009]
First Reported 11/11/2009 - Updated 11/11/2009 - 1 Documents
Talvivaara Mining Company plc - Click to view 360-page
Talvivaara Mining Company plc
FTSE tipped to open modestly higher, with Sainsbury a focus
Business Financial Newswire - PRE-OPEN REPORT: Headline shares are tipped to open twenty to twenty-five points higher, according to financial websites, following a flat session in New York overnight, with supermarketeer Sainsbury a focus.US & ASIAIn the ... [Business Financial Newswire - 11/11/2009]
First Reported 11/11/2009 - Updated 11/11/2009 - 1 Documents
Ark cash consumption in line with expectations
Business Financial Newswire - Ark Therapeutics says it is satisfied with the current financial position of the company.The firm had £28.6m in cash and money market investments at 30 June 2009 and cash consumption since then had been in line with expectations ... [Business Financial Newswire - 11/11/2009]
First Reported 06/17/2009 - Updated 06/17/2009 - 1 Documents
TechMARK movers: Ark and BATM gain
LONDON (SHARECAST) - Privately owned global wound care company AOTI is to use Ark Therapeutics' Kerraboot product as part of its Topical Wound Oxygen Therapy (TWO2) for the treatment of chronic wounds.Kerraboot is a boot-like dressing device used in the ... [ShareCast - 06/17/2009]
First Reported 06/24/2009 - Updated 06/24/2009 - 1 Documents
Imagination Technologies Group PLC - Click to view 360-page
Imagination Technologies Group PLC
TechMARK movers: Imagination soars after profit hike
LONDON (SHARECAST) - Imagination Technologies rallied after the chip designer posted a 56% hike in annual pre-tax profit underpinned by strong licensing and royalty sales.Adjusted pre-tax profit rose to 5m for the 12 months to 30 April 2009 from 3.2m ... [ShareCast - 06/24/2009]
First Reported 06/25/2009 - Updated 06/25/2009 - 1 Documents (in Market News)
NCC Group - Click to view 360-page
NCC Group
TechMARK movers: Micro Focus profits rise
LONDON (SHARECAST) - Acquisitive legacy software specialist Micro Focus reported a 30.8% rise in full year pre-tax profits but warned that the impact of the recent Compuware acquisition is expected to reduce the overall group margin.Adjusted pre-tax profit ... [ShareCast - 06/25/2009]
First Reported 07/01/2009 - Updated 07/01/2009 - 1 Documents (in Corporate Deals)
Small caps round-up: InterCytex, K3 Business Tech, Research Now...
ICX - Intercytex Latest Prices Name Price % Intercytex 5.12p -56.38% Ark Therapeutics 45.50p +2.82% Braemore Resources 4.85p +12.01% Carpathian 18.25p +12.31% Cyril Sweett 33.00p +6.45% Charles Taylor 185.50p -0.40% CustomVis 1.73p +6.13% 77.50p 0.00% ... [ShareCast - 07/01/2009]
First Reported 07/07/2009 - Updated 07/07/2009 - 1 Documents
Domainex and Ark Therapeutics extend drug discovery agreement
: Domainex Ltd (Domainex), a UK-based specialist provider of drug discovery solutions, today announced an extension of its research agreement with Ark Therapeutics Group Ltd (Ark). Under the terms of the agreement Domainex will continue to provide Ark ... [BioPortfolio - 07/07/2009]
First Reported 07/09/2009 - Updated 07/09/2009 - 1 Documents (in Biology)
Domainex, Ark Therapeutics extend drug discovery pact
Domainex Ltd (Domainex), a UK-based specialist provider of drug discovery solutions, announced an extension of its research agreement with Ark Therapeutics Group Ltd (Ark). Under the terms of the agreement Domainex will continue to provide Ark with hit-finding ... [PharmaBiz - 07/09/2009]
First Reported 08/06/2009 - Updated 08/06/2009 - 1 Documents
TechMark movers: IndigoVision jumps on expected higher profits
LONDON (SHARECAST) - IP security systems provider IndigoVision surged after it said improving operating margins will help operating profits for the year to finish "materially ahead" of market expectations.The group said it experienced strong sales, particularly ... [ShareCast - 08/06/2009]
First Reported 08/13/2009 - Updated 08/13/2009 - 1 Documents
TechMARK movers: Alphameric jumps on bid
Aug 2009 LONDON (SHARECAST) - Betting software group Alphameric has received a bid approach, sending its shares to their highest in a year-and-a-half. "The board of directors of Alphameric notes the recent movement in its share price and announces it ... [ShareCast - 08/13/2009]

Quotes

...drugs targeting angiogenic molecules such as VEGF-C is widely considered one of the most promising strategies in the pharmaceutical industry.” "It represents a major asset for commercial partnerships with other companies seeking to pursue this approach.” " Circadian has licensed rights to some parts of its intellectual property portfolio for the development of other products to UK company Ark Therapeutics...
Circadian Technologies is granted key VEGF-C patent in Japan, developing antibody drug for cancer [Proactiveinvestors United Kingdom RSS feed - 08/25/2009]
...The company is also developing its own pipeline of pre-clinical drugs and targets. Dr Trevor Perrior, research director of Domainex, commented, "Domainex is delighted that Ark has decided to extend our productive relationship. The synergy and teamwork between our respective scientists have been outstanding, and this collaboration has already resulted in the achievement of key breakthroughs against very challenging scientific goals. We look forward to taking these programmes to the next stage of their development, with the aim of delivering important new treatments for major life-threatening diseases. The renewal of this contract is a further illustration of the value that clients such as Ark place on the contribution that Domainex is able to bring to their drug research programmes." Domainex provides innovative drug discovery solutions, including computational and medicinal chemistry, gene cloning and protein expression, to phar...
Domainex, Ark Therapeutics extend drug discovery pact [PharmaBiz - 07/09/2009]
...' Dr Nigel Parker, CEO of Ark, said, "We are very pleased with this initiative. There remains a significant unmet need in patients with malignant glioma and approval on a named patient basis is a logical step to making the product more widely available. This is an important milestone and another first for Ark as we believe it is the first time a gene medicine has been approved for use in a Named Patient Supply programme in Europe." Ark Therapeutics Group plc is a specialist healthcare group addressing high value areas of unmet medical need within vascular disease, wound care and...
Ark gets French nod for Named Patient Supply of Cerepro [PharmaBiz - 02/20/2009]

More Content

All (79) | News (77) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (1)
sort by: Date | Relevance
FTSE 100 movers: Figures boost SABMiller [Digital Look - 11/19/2009]
Circadian Technologies CEO Robert Klupacs tells... [Proactive Investors.co.uk - 11/19/2009]
TechMARK movers: Cautiously optimistic Dimension [ShareCast - 11/18/2009]
TechMARK movers: Cable demerger received well [ShareCast - 11/17/2009]
TechMARK movers: Aveva upgraded by Citigroup [Digital Look - 11/16/2009]
TechMARK movers: Aveva upgraded by Citigroup [Find - 11/16/2009]
TechMARK movers: Sinclair deal terminated [Find - 11/13/2009]
TechMARK movers: Sinclair deal terminated [Digital Look - 11/13/2009]
TechMARK movers: Weak US market hits Genus [Digital Look - 11/12/2009]
TechMARK movers: Micro Focus please... [Digital Look - 11/11/2009]
TechMARK movers: Micro Focus pleases investors [Digital Look - 11/11/2009]
Ark cash consumption in line with expectations [Business Financial Newswire - 11/11/2009]
FTSE tipped to open modestly higher, with Sains... [Business Financial Newswire - 11/11/2009]
TechMARK movers: Disposal dividend boosts Microgen [ShareCast - 11/03/2009]
Week Ahead: 9-13 November [Investors Chronicle - 11/03/2009]
Core-satellite approach comes into its own [Citywire - 11/03/2009]
Circadian Technologies subsidiary terminates li... [Proactiveinvestors United Kingdom RSS feed - 10/29/2009]
Circadian Technologies subsidiary terminates li... [Proactive Investors.co.uk - 10/29/2009]
TechMARK movers: Standard increases Kewill stake [ShareCast - 10/26/2009]
TechMARK movers: Positive reaction to Fidessa t... [Find - 10/23/2009]
Hybridan's Small Cap Wrap - 20-10-09 [Interactive Investor Articles - 10/20/2009]
TechMARK movers: Gresham sells storage unit [ShareCast - 10/19/2009]
Systems Biology Ireland uses HP Extreme Data St... [MTB Europe - 10/15/2009]
Need to know: Burberry sales up ... Diageo shar... [Times Online - 10/15/2009]
Burberry sales up ... Diageo shares down ... Fr... [Times Online - 10/14/2009]
TechMARK movers: Phytopharm shares soar [ShareCast - 10/14/2009]
Circadian Technologies Limited (CIR.AX) Achieve... [BioSpace - 10/14/2009]
TechMARK movers: Sinclair Pharma lower [ShareCast - 10/12/2009]
HP to kit out new Systems Biology CSET with sto... [Silicon Republic - 10/07/2009]
TechMARK movers: E2V revises debt facilities [ShareCast - 09/30/2009]
1 2 3
In Focus
  •  
Chris Geoghegan, Michael Dell, Charles Taylor, [more]
  •  
CIRCADIAN TECHNOLOGIES LIMITED, Innovation Group PLC, SkyePharma plc, [more]
  •  
Food and Drug Administration, University College Dublin, Financial Services Authority, [more]
  •  
cachexia, malignant, glioma, [more]
  •  
London, Antofagasta, Kuopio (Finland), [more]
  •  
United Kingdom, Cameroon, Ireland, [more]
  •  
Biology, Medicine, Biotechnology, [more]
  •  
Pharma & Biotech, Banking & Financial Services, Telecom, [more]
ShareCast, Able2Act, PharmaBiz, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Small Cap Stocks Battling Brain Cancer [Biotech Sector and Stocks Analysis from Seeking ... - 09/07/2009]
Mike Havrilla submits:Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH ...
1

  •  
  •  
  •